"W.R. Hambrecht downgraded the company, which makes devices to monitor blood sugar levels for diabetics, to "hold" from "buy," citing low visibility and some weak data for July and August. The firm also said it thinks current 2003 estimates are too aggressive."
oct 11, 2002
"Therasense down-$3.37 to $5.16, said Friday third-quarter sales growth, while up 96% from a year ago, is below previous expectations. A third-quarter operating loss of 24 cents a share is expected. Analysts surveyed by First Call expected a loss of a penny a share. The company blamed slow reorders from retailers and wholesalers and promotional costs. It makes glucose monitoring kits."
aahathectchoo ...excuse me
buy out at 27 fifteen months later
makes good therasense to me
6X 250mm est '08 revs = 1.5 b - divided by 26 mil shares = $57/sh buyout in 2008. but the 250mm is just a guess. the 6 bil glucose testing mkt is growing 10% a year.